BACKGROUND: Ethambutol is used for the treatment of tuberculosis in cases where there is isoniazid resistance. We examined the emergence of drug resistance to ethambutol monotherapy in pharmacokinetic-pharmacodynamic studies of a hollow-fiber system. METHODS: Dose-effect and dose-scheduling studies were performed with ethambutol and log-phase growth Mycobacterium tuberculosis to identify exposures and schedules linked to optimal kill and resistance suppression. In one study, after 7 days of daily ethambutol, 300 mg isoniazid per day was administered to each system to determine its early bactericidal activity. RESULTS: Efflux-pump blockage reduced the mutation frequency to ethambutol 64-fold. In dose-effect studies, ethambutol had a maximal early bactericidal activity of 0.22 log10 colony-forming units/mL/day, as is encountered in patients. By day 7, resistance to both ethambutol and isoniazid had increased. Previous exposure to ethambutol halted isoniazid early bactericidal activity. Daily therapy, as opposed to more intermittent therapy, was associated with the least proportion of efflux-pump-driven resistance, consistent with a time-driven effect. Microbial kill was best explained by the ratio of area under the concentration-time curve to minimum inhibitory concentration (r2 = 0.90). CONCLUSION: The induction of an efflux pump that reduces the effect of multiple drugs provides an alternative pathway to sequential acquisition of mutations in the development of multiple drug resistance.
BACKGROUND:Ethambutol is used for the treatment of tuberculosis in cases where there is isoniazid resistance. We examined the emergence of drug resistance to ethambutol monotherapy in pharmacokinetic-pharmacodynamic studies of a hollow-fiber system. METHODS: Dose-effect and dose-scheduling studies were performed with ethambutol and log-phase growth Mycobacterium tuberculosis to identify exposures and schedules linked to optimal kill and resistance suppression. In one study, after 7 days of daily ethambutol, 300 mg isoniazid per day was administered to each system to determine its early bactericidal activity. RESULTS: Efflux-pump blockage reduced the mutation frequency to ethambutol 64-fold. In dose-effect studies, ethambutol had a maximal early bactericidal activity of 0.22 log10 colony-forming units/mL/day, as is encountered in patients. By day 7, resistance to both ethambutol and isoniazid had increased. Previous exposure to ethambutol halted isoniazid early bactericidal activity. Daily therapy, as opposed to more intermittent therapy, was associated with the least proportion of efflux-pump-driven resistance, consistent with a time-driven effect. Microbial kill was best explained by the ratio of area under the concentration-time curve to minimum inhibitory concentration (r2 = 0.90). CONCLUSION: The induction of an efflux pump that reduces the effect of multiple drugs provides an alternative pathway to sequential acquisition of mutations in the development of multiple drug resistance.
Authors: Amy Sarah Ginsburg; Samuel C Woolwine; Nancy Hooper; William H Benjamin; William R Bishai; Susan E Dorman; Timothy R Sterling Journal: N Engl J Med Date: 2003-11-13 Impact factor: 91.245
Authors: G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor Journal: Antimicrob Agents Chemother Date: 2009-05-18 Impact factor: 5.191
Authors: Fernanda S Spies; Pedro E Almeida da Silva; Marta O Ribeiro; Maria Lucia Rossetti; Arnaldo Zaha Journal: Antimicrob Agents Chemother Date: 2008-06-09 Impact factor: 5.191
Authors: P R Donald; F A Sirgel; A Venter; D P Parkin; H I Seifart; B W van de Wal; J S Maritz; P B Fourie Journal: Expert Rev Anti Infect Ther Date: 2003-06 Impact factor: 5.091
Authors: Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191
Authors: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano Journal: J Infect Dis Date: 2004-09-24 Impact factor: 5.226
Authors: Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor Journal: Am J Respir Crit Care Med Date: 2011-04-21 Impact factor: 21.405
Authors: Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191